Assessing Harmony Biosciences (HRMY) Valuation After Softer Earnings But Stronger Free Cash Flow

Harmony Biosciences Holdings (HRMY) is back in focus after its latest quarterly report showed net income of US$32.49 million for the March 2026 quarter, lower than the US$45.56 million reported a year earlier. See our latest analysis for Harmony Biosciences Holdings. Despite the softer earnings and a series of routine governance updates at the 2026 Annual Meeting, the stock has retreated, with the share price down 16.44% over 90 days and the year to date share price return down 19.50%. The 1 year total shareholder return is down 14.20%, pointing to fading momentum after a weaker run. If this earnings reaction has you reassessing your watchlist, it could be a good moment to broaden your search and check out 19 top founder-led companies So with earnings softer, free cash flow stronger and the share price weaker, should you see Harmony Biosciences as trading below its underlying worth, or assume the market is already pricing in any future growth? Most Popular Narrative: 36.4% Undervalued Harmony Biosciences' most followed valuation narrative pegs fair value at about $47.30 per share, well above the last close of $30.09, which sets up a clear valuation gap for investors to assess. The analysts have a consensus price target of $50.455 for Harmony Biosciences Holdings based on their expectations of its future earnings growth, profit margins and other risk factors. However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of $70.0, and the most bearish reporting a price target of just $31.0. Read the complete narrative. Curious what underpins that fair value gap? The narrative leans on a specific path for revenue expansion, rising margins and a future earnings multiple that differs from today. The full story connects these moving parts into one valuation case. Result: Fair Value of $47.30 (UNDERVALUED) Have a read of the narrative in full and understand what's behind the forecasts. However, this depends on Wakix maintaining its edge and key trials remaining on track, while legal and generic risks could quickly change how the story is framed. Find out about the key risks to this Harmony Biosciences Holdings narrative. Next Steps If the mixed sentiment in this story leaves you unsure, take a closer look at the data now and weigh the upside for yourself with 3 key rewards Looking for more investment ideas? If Harmony Biosciences is on your radar, do not stop there. Broaden your opportunity set with targeted stock ideas built from hard numbers, not hype. Target resilience by reviewing companies in the 65 resilient stocks with low risk scores that may better fit your comfort with volatility and downside protection. Chase value by checking the screener containing 21 high quality undiscovered gems before others catch on to businesses that already show quality fundamentals. Prioritise financial strength by using the solid balance sheet and fundamentals stocks screener (45 results) so you are not left holding stocks with fragile foundations when conditions change. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.